A  ||| S:0 E:2 ||| DT
problem  ||| S:2 E:10 ||| NN
of  ||| S:10 E:13 ||| IN
the  ||| S:13 E:17 ||| DT
HIV  ||| S:17 E:21 ||| NNP
drug  ||| S:21 E:26 ||| NN
resistance  ||| S:26 E:37 ||| NN
The  ||| S:37 E:41 ||| DT
wide  ||| S:41 E:46 ||| JJ
use  ||| S:46 E:50 ||| NN
of  ||| S:50 E:53 ||| IN
the  ||| S:53 E:57 ||| DT
highly  ||| S:57 E:64 ||| RB
active  ||| S:64 E:71 ||| JJ
antiretroviral  ||| S:71 E:86 ||| JJ
therapy  ||| S:86 E:94 ||| NN
( ||| S:94 E:95 ||| -LRB-
HAART ||| S:95 E:100 ||| NNP
)  ||| S:100 E:102 ||| -RRB-
of  ||| S:102 E:105 ||| IN
HIV  ||| S:105 E:109 ||| NNP
infection  ||| S:109 E:119 ||| NN
leads  ||| S:119 E:125 ||| VBZ
to  ||| S:125 E:128 ||| TO
the  ||| S:128 E:132 ||| DT
HIV  ||| S:132 E:136 ||| NNP
drug  ||| S:136 E:141 ||| NN
resistance ||| S:141 E:151 ||| NN
.  ||| S:151 E:153 ||| .
The  ||| S:153 E:157 ||| DT
simultaneous  ||| S:157 E:170 ||| JJ
formation  ||| S:170 E:180 ||| NN
of  ||| S:180 E:183 ||| IN
the  ||| S:183 E:187 ||| DT
resistance  ||| S:187 E:198 ||| NN
to  ||| S:198 E:201 ||| TO
different  ||| S:201 E:211 ||| JJ
groups  ||| S:211 E:218 ||| NNS
of  ||| S:218 E:221 ||| IN
antiviral  ||| S:221 E:231 ||| JJ
drugs  ||| S:231 E:237 ||| NNS
compromises  ||| S:237 E:249 ||| VBP
the  ||| S:249 E:253 ||| DT
efficacy  ||| S:253 E:262 ||| NN
of  ||| S:262 E:265 ||| IN
HAART ||| S:265 E:270 ||| NNP
.  ||| S:270 E:272 ||| .
Thus ||| S:272 E:276 ||| RB
,  ||| S:276 E:278 ||| ,
the  ||| S:278 E:282 ||| DT
problem  ||| S:282 E:290 ||| NN
of  ||| S:290 E:293 ||| IN
the  ||| S:293 E:297 ||| DT
drug  ||| S:297 E:302 ||| NN
resistance  ||| S:302 E:313 ||| NN
becomes  ||| S:313 E:321 ||| VBZ
of  ||| S:321 E:324 ||| IN
an  ||| S:324 E:327 ||| DT
enormous  ||| S:327 E:336 ||| JJ
significance ||| S:336 E:348 ||| NN
.  ||| S:348 E:350 ||| .
In  ||| S:350 E:353 ||| IN
this  ||| S:353 E:358 ||| DT
review ||| S:358 E:364 ||| NN
,  ||| S:364 E:366 ||| ,
a  ||| S:366 E:368 ||| DT
definition  ||| S:368 E:379 ||| NN
of  ||| S:379 E:382 ||| IN
the  ||| S:382 E:386 ||| DT
resistance  ||| S:386 E:397 ||| NN
is  ||| S:397 E:400 ||| VBZ
given ||| S:400 E:405 ||| VBN
;  ||| S:405 E:407 ||| :
the  ||| S:407 E:411 ||| DT
problem  ||| S:411 E:419 ||| NN
of  ||| S:419 E:422 ||| IN
the  ||| S:422 E:426 ||| DT
drug-resistant  ||| S:426 E:441 ||| JJ
strains  ||| S:441 E:449 ||| JJ
transmission  ||| S:449 E:462 ||| NN
is  ||| S:462 E:465 ||| VBZ
discussed ||| S:465 E:474 ||| VBN
;  ||| S:474 E:476 ||| :
the  ||| S:476 E:480 ||| DT
assays  ||| S:480 E:487 ||| NN
used  ||| S:487 E:492 ||| VBN
for  ||| S:492 E:496 ||| IN
resistance  ||| S:496 E:507 ||| NN
testing  ||| S:507 E:515 ||| NN
are  ||| S:515 E:519 ||| VBP
described ||| S:519 E:528 ||| VBN
;  ||| S:528 E:530 ||| :
recommendations  ||| S:530 E:546 ||| NNS
for  ||| S:546 E:550 ||| IN
the  ||| S:550 E:554 ||| DT
antiviral  ||| S:554 E:564 ||| JJ
drug-resistance  ||| S:564 E:580 ||| JJ
testing  ||| S:580 E:588 ||| NN
are  ||| S:588 E:592 ||| VBP
given ||| S:592 E:597 ||| VBN
.  ||| S:597 E:599 ||| .
